• Register
  • Login
  • Subscribe
  • Contact Us

Medicines with the Active Ingredient Combination Rosuvastatin and Ezetimib (atc: C10ba06)

GermanyTenders notice for Medicines with the Active Ingredient Combination Rosuvastatin and Ezetimib (atc: C10ba06). The reference ID of the tender is 56402532 and it is closing on 28 Jul 2023.

Tender Details

  • Country: Germany
  • Summary: Medicines with the Active Ingredient Combination Rosuvastatin and Ezetimib (atc: C10ba06)
  • DET Ref No: 56402532
  • Deadline: 28 Jul 2023
  • Financier: Self Financed
  • Purchaser Ownership: Government
  • Tender Value: Refer Document
  • Notice Type: Tender
  • Document Ref. No.: 419795-2021
  • Purchaser's Detail:
    Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
  • Description:
  • Document Type: Contract Notice
    Title: Medicines with the drug combination Rosuvastatin and Ezetimib (ATC: C10BA06)
    Reference Number: AOK SAN 2021 Openhouse 49
    Contract Type: Supplies
    Description: The subject of this publication is the conclusion of non-exclusive discount contracts pursuant to Section 130a (8) SGB V to medicines with the active ingredient combination Rosuvastatin and Ezetimib (ATC: C10BA06) as part of a so-called "Open-House model". Under the preservation of uniform contract terms and a uniform access procedure, all appropriate and interested pharmaceutical companies or communities of pharmaceutical companies is offered to the conclusion or accession to a discount agreement according to ยง130a (8) SGB V to the active ingredients mentioned under Section B. Interested pharmaceutical companies may request the participation documents as well as the respective contract in the contact address referred to in i.1). The prerequisite for the conclusion of a contract is that the interested pharmaceutical company fully completed and signed the requested participation documents.

    33600000 - Pharmac ...
  • Documents:

 Tender Notice

If you are registered member, kindly login to view full details of this tender notice:

CLICK HERE TO LOGIN

Medicines with the Active Ingredient Combination Rosuvastatin and Ezetimib (atc: C10ba06) - Germany Tender

The AOK SAXONY-ANHALT, a Government sector organization in Germany, has announced a new tender for Medicines with the Active Ingredient Combination Rosuvastatin and Ezetimib (atc: C10ba06). This tender is published on GermanyTenders under DET Ref No: 56402532 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2023-07-28.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.

GermanyTenders Features

GermanyTenders Features

Fresh and verified Tenders from Germany. Find, search and filter Tenders/Call for bids/RFIs/RFPs/RFQs/Auctions published by the government, public sector undertakings (PSUs) and private entities.

  • 1,000+ Tenders
  • Verified Tenders Only
  • New Tenders Every Day
  • Tenders Result Data
  • Archive & Historical Tenders Access
  • Consultants for RFI/RFP/RFQ
  • Tender Notifications & Alerts
  • Search, Sort, and Filter Tenders
  • Bidding Assistance & Consulting
  • Customer Support
  • Publish your Tenders
  • Export data to Excel
  • API for Tender Data
  • Tender Documents
Tender Experts

Get A Call From Tender Experts

Fill out the form below and you will receive a call from us within 24 hours.

Thank You for Contacting GermanyTenders !!
Email Id is already exist !!
Captcha Image
Invalid Captcha !

Get FREE SAMPLE TENDERS from Germany in your email inbox.

  Chat with us